Anti-Retroviral Agents: Sunlenca (lenacapavir) and Trogarzo (ibalizumab-uiyk)
Customize your policy alerts
Sign up for all Mass General Brigham Health Plan policy alerts
Know when Mass General Brigham Health Plan releases new policies or updates existing guidance.
Monitor payer policy activity
Prior authorization criteria for Sunlenca and Trogarzo under the MassHealth medical benefit for adults with heavily treatment-experienced, multidrug-resistant HIV-1.
Trogarzo coverage now requires inadequate response or an adverse reaction to Rukobia or Sunlenca, or contraindication to both drugs.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.